Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Timo K. van den Berg"'
Autor:
Hanke L. Matlung, Jeanette H.W. Leusen, Thomas Valerius, Timo K. van den Berg, Taco W. Kuijpers, Katka Franke, Jan M. Prins, Paul J.J.H. Verkuijlen, Karin Schornagel, Steffen Kahle, Michel van Houdt, J.H. Marco Jansen, Thies Rösner, Toine ten Broeke, Louise W. Treffers
Therapeutic monoclonal antibodies (mAb), directed toward either tumor antigens or inhibitory checkpoints on immune cells, are effective in cancer therapy. Increasing evidence suggests that the therapeutic efficacy of these tumor antigen–targeting m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ed4d0b16a582b60db76330392fc3c53
https://doi.org/10.1158/2326-6066.c.6550411.v1
https://doi.org/10.1158/2326-6066.c.6550411.v1
Autor:
Hanke L. Matlung, Jeanette H.W. Leusen, Thomas Valerius, Timo K. van den Berg, Taco W. Kuijpers, Katka Franke, Jan M. Prins, Paul J.J.H. Verkuijlen, Karin Schornagel, Steffen Kahle, Michel van Houdt, J.H. Marco Jansen, Thies Rösner, Toine ten Broeke, Louise W. Treffers
Supplementary Materials and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5df862a7afcfbe329059688740137f9
https://doi.org/10.1158/2326-6066.22543807
https://doi.org/10.1158/2326-6066.22543807
Autor:
Hanke L. Matlung, Jeanette H.W. Leusen, Thomas Valerius, Timo K. van den Berg, Taco W. Kuijpers, Katka Franke, Jan M. Prins, Paul J.J.H. Verkuijlen, Karin Schornagel, Steffen Kahle, Michel van Houdt, J.H. Marco Jansen, Thies Rösner, Toine ten Broeke, Louise W. Treffers
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf9b8f6a57e4ee63d57d35612a94a925
https://doi.org/10.1158/2326-6066.22543804.v1
https://doi.org/10.1158/2326-6066.22543804.v1
Autor:
Thomas Valerius, Timo K. van den Berg, Jeanette H.W. Leusen, Frank Beurskens, Mitchell Evers, J.H. Marco Jansen, Hanke L. Matlung, Francesca Montenegro, Steffen Kahle, Thies Rösner
Three FDA-approved epidermal growth factor receptor (EGFR) antibodies (cetuximab, panitumumab, necitumumab) are clinically available to treat patients with different types of cancers. Interestingly, panitumumab is of human IgG2 isotype, which is ofte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d53396a21ebf39f28cac8bff56a7cb02
https://doi.org/10.1158/1535-7163.c.6537996.v1
https://doi.org/10.1158/1535-7163.c.6537996.v1
Autor:
Thomas Valerius, Timo K. van den Berg, Jeanette H.W. Leusen, Frank Beurskens, Mitchell Evers, J.H. Marco Jansen, Hanke L. Matlung, Francesca Montenegro, Steffen Kahle, Thies Rösner
The Figure S1 shows: A) Maximal EGFR binding of different EGFR antibodies B) Complement factor binding and deposition by combinations of EGFR IgG1/IgG1, IgG1/IgG2 and IgG2/IgG2 antibodies C) EGFR expression of A431 ctrl and A431 CD47 Ko cells D) Targ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00d338748da494198339e5d7b3f89bec
https://doi.org/10.1158/1535-7163.22505232.v1
https://doi.org/10.1158/1535-7163.22505232.v1